BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
IPO Year:
Exchange: NASDAQ
Website: briacell.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2022 | $25.00 | Buy | HC Wainwright & Co. |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
3 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
3 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
3 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
3 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
3 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
3 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
Fastest customizable press release news feed in the world
Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitorFourth consecutive positive DSMB recommendation supports the favorable safety profile observed to datePhase 3 study is being conducted under FDA Fast Track Designation, reflecting the significant unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the ind
79 clinical sites across 23 US states are currently enrolling patients in BriaCell's pivotal Phase 3 study in metastatic breast cancer (MBC) Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University have now joined BriaCell's extensive national network PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the addition of several key large cancer centers to its ongoing pivotal Phase 3 clinical study (Clinica
Collaboration with MSK's Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a collaboration with Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator Cohort program to accelerate the clinical development of Bria-OTS+, BriaCell's next generation personalized
Biomarkers identified in BriaCell's Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC)No new safety or tolerability issues identified in pooled analysis of ongoing pivotal Phase 3 study PHILADELPHIA and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces encouraging clinical biomarker data in its ongoing pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor (CPI) in m
Biomarkers identified in Phase 2 study demonstrate similar trends in ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC)Positive delayed-type hypersensitivity (DTH) – a potential biomarker predictive of improved clinical outcomes – significantly associated with longer progression-free survival (PFS) in a blinded analysis of all current Phase 3 patients No new safety or tolerability issues identified PHILADELPHIA and VANCOUVER, British Columbia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform can
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting preclinical Bria-OTS+ data at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, held November 7-9, 2025, in National Harbor, MD. The details are listed below. Title: Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance Abstract Number
Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell's Bria-OTS+ platformBria-OTS+, a novel personalized, off-the-shelf, semi-allogeneic cellular immunotherapy may address urgent unmet medical needs for patients with cancer This study was conducted in collaboration with the NCI PHILADELPHIA and VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the publication of the mechanism of action of its next generat
US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancerExpands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical needPrincipal Investigator: Dr. William Oh, MD, Yale Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the National Cance
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company's board of directors has approved the consolidation (the "Consolidation") of the Company's issued and outstanding common shares (the "Common Shares") on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce its acceptance into Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator 2025 Cohort program. This project aims to accelerate the clinical development of Bria-OTS+, BriaCell's next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. As one of the world's foremost canc
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
HC Wainwright & Co. initiated coverage of BriaCell Therapeutics with a rating of Buy and set a new price target of $25.00
10-K - BriaCell Therapeutics Corp. (0001610820) (Filer)
8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)
S-8 - BriaCell Therapeutics Corp. (0001610820) (Filer)
SCHEDULE 13G - BriaCell Therapeutics Corp. (0001610820) (Subject)
8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)
EFFECT - BriaCell Therapeutics Corp. (0001610820) (Filer)
424B4 - BriaCell Therapeutics Corp. (0001610820) (Filer)
FWP - BriaCell Therapeutics Corp. (0001610820) (Subject)
S-1/A - BriaCell Therapeutics Corp. (0001610820) (Filer)
S-1/A - BriaCell Therapeutics Corp. (0001610820) (Filer)
Live finance-specific insights
The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation. The Company recorded total revenue of $5.6 million during the three months ended April 30, 2023, the highest quarterly revenue total the Company has recorded. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023. "As we usher in Fiscal Year 2024, we carry with us a strong momentum from the impressive
Live Leadership Updates
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the susp
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaPro Therapeutics Corp. ("BriaPro" or the "Company"), a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2023 held on January 30, 2024 (the "Meeting"). A total of 5,375,071 common shares of the Company (the "Common Shares") were voted, representing 33.63% of the Company's issued and outstanding Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the formation of its medical advisory board and the appointment of three distinguished breast cancer key opinion leaders (KOLs) Massimo Cristofanilli, MD, FACP, Sara A. Hurvitz, MD, FACP, and Adam M. Brufsky, MD, PhD, as well as the addition of Charles Sidman, PhD, MBA, to its scientific advisory board. "We are extremely privileged to have these leading experts on state-of-the art breast cancer cli
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2022 held on February 9, 2023 (the "Meeting"). A total of 6,663,370 common shares of the Company (the "Common Shares") were voted, representing 42.94% of the Company's issued and outstanding Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that it has appointed leading immunologist, Alexander Kharazi, M.D., Ph.D., to its Scientific Advisory Board. Dr. Kharazi co-invented Bria-IMT™, BriaCell's lead clinical candidate, in collaboration with Dr. Charles L. Wiseman, BriaCell's Founder and Principal Research Advisor. Dr. Kharazi currently serves as Chief Technology Officer at Stemedica Cell Technologies, Inc. His experience include
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces the appointment of Giuseppe Del Priore, MD, MPH, as the Company's Chief Medical Officer (CMO), effective today. Dr. Del Priore will oversee the clinical and regulatory aspects of BriaCell's current and upcoming clinical trials including the ongoing Phase I/IIa combination study of BriaCell's lead candidate, Bria-IMT™, with Incyte's checkpoint inhibitors, retifanlimab and epacadostat in advanced bre
NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ
This live feed shows all institutional transactions in real time.
SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13G/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13G - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13G/A - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13G - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13G - BriaCell Therapeutics Corp. (0001610820) (Subject)
SC 13G/A - BriaCell Therapeutics Corp. (0001610820) (Subject)